OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引：3

作者：

Robson, Mark E. ^{[1
]}

Im, Seock-Ah ^{[2
]}

Senkus, Elzbieta ^{[3
]}

Xu, Binghe ^{[4
]}

Domchek, Susan ^{[5
]}

Masuda, Norikazu ^{[6
]}

Delaloge, Suzette ^{[7
]}

Li, Wei ^{[8
]}

Tung, Nadine ^{[9
]}

Armstrong, Anne ^{[10
]}

Wu, Wenting ^{[11
]}

Goessl, Carsten ^{[11
]}

Runswick, Sarah ^{[12
]}

Conte, Pierfranco ^{[13
,14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Med Univ Gdansk, Gdansk, Poland

[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA

[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan

[7] Inst Gustave Roussy, Villejuif, France

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[11] AstraZeneca, Gaithersburg, MD USA

[12] AstraZeneca, Macclesfield, Cheshire, England

[13] Univ Padua, Padua, Italy

[14] Ist Oncol Veneto IRCCS, Padua, Italy

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-CT038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT038

引用

页数：2

共 50 条

[31] Clinical outcomes, treatment patterns and health resource utilization (HRU) among metastatic breast cancer (mbc) patients (pts) with germline BRCA mutation (gBRCAm) [J].

Quek, R. ;

Mardekian, J. .

ANNALS OF ONCOLOGY, 2018, 29

[32] Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? [J].

Kuemmel, Sherko ;

Jackisch, Christian ;

Mueller, Volkmar ;

Schneeweiss, Andreas ;

Klawitter, Sandra ;

Lux, Michael P. .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :5423-5431

[33] OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) [J].

Robson, Mark ;

Tutt, Andrew ;

Balmana, Judith ;

Kaufman, Bella ;

Garber, Judy ;

Geyer, Charles ;

Ford, James ;

Sharma, Priyanka ;

Stuart, Mary ;

Mann, Helen ;

Fasching, Peter A. .

CANCER RESEARCH, 2015, 75

[34] Germline BRCA1 and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry. [J].

Fasching, Peter A. ;

Hu, Chunling ;

Hart, Steven ;

Hartkopf, Andreas D. ;

Taran, Florin A. ;

Janni, Wolfgang ;

Tesch, Hans ;

Haeberle, Lothar ;

Ettl, Johannes ;

Overkamp, Friedrich ;

Lux, Michael P. ;

Luftner, Diana ;

Wallwiener, Markus ;

Mueller, Volkmar ;

Kolberg, Hans-Christian ;

Fehm, Tanja N. ;

Wallwiener, Diethelm ;

Brucker, Sara ;

Schneeweiss, Andreas ;

Couch, Fergus .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[35] Cost-effectiveness analysis of eribulin (E) versus treatment of physician's choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC). [J].

Montero, Alberto J. ;

Avancha, Kiran Kumar Venkata Raja ;

Gluck, Stefan ;

Lopes, Gilberto de Lima .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[36] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation [J].

Gelmon, Karen ;

Walker, Graham P. ;

Fisher, Graham V. .

CANCER RESEARCH, 2018, 78 (04)

[37] Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer [J].

Tuffaha, Haitham ;

Scuffham, Paul .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 :64-65

[38] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study [J].

Xu, Binghe ;

Sun, Tao ;

Shi, Yanxia ;

Cui, Jiuwei ;

Yin, Yongmei ;

Ouyang, Quchang ;

Liu, Qiang ;

Zhang, Qingyuan ;

Chen, Yiding ;

Wang, Shouman ;

Wang, Xiaojia ;

Tong, Zhongsheng ;

Zhong, Yahua ;

Wang, Jiayu ;

Yan, Min ;

Yan, Xi ;

Wang, Chuan ;

Feng, Jifeng ;

Wang, Xiuli ;

Hu, Gang ;

Cheng, Ying ;

Ge, Ruimin ;

Zhu, Zhaoyin ;

Zhang, Wa ;

Shao, Zhimin .

BREAST CANCER RESEARCH AND TREATMENT, 2022, 197 (3) :489-501

[39] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study [J].

Binghe Xu ;

Tao Sun ;

Yanxia Shi ;

Jiuwei Cui ;

Yongmei Yin ;

Quchang Ouyang ;

Qiang Liu ;

Qingyuan Zhang ;

Yiding Chen ;

Shouman Wang ;

Xiaojia Wang ;

Zhongsheng Tong ;

Yahua Zhong ;

Jiayu Wang ;

Min Yan ;

Xi Yan ;

Chuan Wang ;

Jifeng Feng ;

Xiuli Wang ;

Gang Hu ;

Ying Cheng ;

Ruimin Ge ;

Zhaoyin Zhu ;

Wa Zhang ;

Zhimin Shao .

Breast Cancer Research and Treatment, 2023, 197 :489-501

[40] Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation [J].

J.-S. Frenel ;

A. Lusque ;

S. Delaloge ;

J.-M. Ferrero ;

T. Bachelot ;

I. Desmoulins ;

C. Levy ;

J.-C. Eymard ;

A. Gonçalves ;

A. Patsouris ;

M. A. Mouret Reynier ;

M. J.-C. Thery ;

T. Petit ;

L. Cabel ;

L. Uwer ;

M. Debled ;

M. Chevrot ;

A. Mailliez ;

W. Jacot ;

T. de La Motte Rouge .

British Journal of Cancer, 2023, 128 :2072-2080

← 1 2 3 4 5 →